Navigation Links
Evotec Reports Positive Proof-of-Concept Top-Line Results with,Insomnia Drug Candidate EVT 201

-tolerated at both doses without any serious adverse events.

Further analysis of the remaining secondary endpoints is ongoing.

Jorn Aldag, President and Chief Executive Officer, Evotec AG, said: "We are very pleased with the positive outcome of this clinical trial. Our first drug with proof-of-concept in patients is a major milestone in Evotec's transition into a CNS focused biopharmaceutical company."

Commenting on the results, Dr John Kemp, Chief Research & Development Officer, Evotec AG, added: "We have always considered that EVT 201 has the potential to help patients to fall asleep quickly, help them stay asleep during the night and allow them to awake in the morning feeling refreshed and without any hang-over effect. It thereby meets the major needs of insomniac patients without the need for a sustained release formulation. These results confirm that potential in the primary patient population."

Dr Tim Tasker, Executive Vice President Clinical Development, Evotec AG, added: "The results provide our first evidence that this partial agonist is effective in patients. The profile shows large effects on sleep onset and maintenance without any subjective evidence of hang-over the next day."

Principal Investigator Dr James Walsh, Executive Director of the Sleep Medicine and Research Center, St John's Mercy Medical Center, Chesterfield, Missouri, US, said: "This first study of EVT 201 in patients provided highly significant and robust effects upon polysomnographically measured sleep for both doses. In addition patients reported an improved quality of sleep. Ratings of alertness in the morning were not impaired and findings on DSST were quite small. These are encouraging results which offer significant promise for the drug as a treatment for insomnia patients."

A second Phase II clinical trial of EVT 201 in elderly patients with chronic insomnia for further differentiation is ongoing. Top-line results from this trial are exp
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:5/19/2008)... Data to Be Presented at the 2008 Annual European ...n League Against Rheumatism (EULAR) -, - Initiati...cond Half of 2008 ...dea Biosciences, Inc.,(Nasdaq: RDEA ) today annou...ndidate for the treatment of patients with gout, R...
(Date:5/19/2008)...Safety Study That Government Scientists Refused To... Risks Says SafeMinds, ATLANTA, May 19 /PRNewsw... that infant monkeys given vaccines officially rec...diatrics (AAP) exhibited autism-like,symptoms. Lea... Pittsburgh,and colleagues presented study results...
(Date:5/19/2008)...E, France, May 19 /- IPSOGEN SA (Mars...ops and markets molecular diagnostic,assays for bl...hers from,the University of Texas MD Anderson Canc...sults of two studies on the Genomic Grade index (G...om May 30 to June 3, 2008. The data,indicate that ...
(Date:5/18/2008)...l Digestive Disease Week data highlight effects of... IBS-C, SAN DIEGO, May 18 /- New stu...) (lubiprostone) 8 mcg lead to significant relief,...th Constipation (IBS-C).,These results were presen...est annual international meeting of digestive dise...
Breaking Medicine Technology:Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 3Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 4Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 5Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists 2Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer 2Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer 3Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer 4New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 2New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 3New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 4New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 5New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 6New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 7Handbook of cancer prevention launched by ESMO 11508 1Handbook of cancer prevention launched by ESMO 11508 2Newly Published Study Demonstrates Return on Investment for Employee Wellness Program 11503 1Newly Published Study Demonstrates Return on Investment for Employee Wellness Program 11503 2Newly Published Study Demonstrates Return on Investment for Employee Wellness Program 11503 3Lumenis 28R 29 Seeks Shareholder Approval of Proposed Class Action Settlement 11501 1Lumenis 28R 29 Seeks Shareholder Approval of Proposed Class Action Settlement 11501 2Michael Beland Named as OrthoSynetics 28TM 29 Corporate Controller 11496 1Michael Beland Named as OrthoSynetics 28TM 29 Corporate Controller 11496 2
...rstCall/ --,Advanced Magnetics today announced tha...r clinical studies of ferumoxytol as an,intravenou...uring,the National Kidney Foundation (NKF) 2007 Sp...ough 14th in Orlando, Florida. Two,posters contain...esday, April 11, 2007 at approximately 5:30 pm ET....
...ntia,Biopharmaceuticals, Inc. (NASDAQ: ABPI), pres...merican Academy of Allergy, Asthma, and,Immunology...,posters discussed findings from a survey of 202 o..., U.K., France, and Germany on the,burden of chron...the fungal etiology of CS, and the differences in ...
Other Medicine Technology:Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 2Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 3Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 4Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 2Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 3Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 4Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 5
(Date:5/20/2008)...less than 5% trust magazines or advertising for,tr...-USNewswire/ -- The Physicians Coalition,for Injec...nd the health and,beauty community RealSelf.com ( ...of a joint survey reporting that 40% of consumers ...y 58% of consumers feel FDA approval,of an injecta...
(Date:5/20/2008)...ay 20 /PRNewswire-FirstCall/ -- Mercury Computer,S...of specialized,high-performance computing solutio...g applications, announced that management will pre...sday, May 29, 2008 at the Cowen and,Company 20/20 ...e will be,held at the New York Palace Hotel, in Ne...
(Date:5/20/2008)...ped approaches to designing a preventive HIV vacci...us Diseases (NIAID), part of the National Institut... the study of B cells, immune cells that can produ... The $15.6 million, five-year program will strengt...ccine research through a network of 10 research te...
(Date:5/20/2008)...ay 20 /PRNewswire/ -- New research that delivers,i...d competitive,intelligence data gathering for the ...ice Database, an online research repository manage...LLC., To review sample key findings and key metri...ks to each study at this address:, http://www3.bes...
Breaking Medicine News(10 mins):Health News:New Survey Suggests That Consumers Are Naive to the Risk of Botox Parties and the Importance of FDA Approval for Cosmetic Injectables 2Health News:New Survey Suggests That Consumers Are Naive to the Risk of Botox Parties and the Importance of FDA Approval for Cosmetic Injectables 3Health News:New Survey Suggests That Consumers Are Naive to the Risk of Botox Parties and the Importance of FDA Approval for Cosmetic Injectables 4Health News:Mercury Computer Systems to Present at the Cowen and Company 20/20 Technology-Media-Telecom Conference on May 29, 2008 2Health News:NIAID to advance B-cell approach to HIV vaccines 2Health News:NIAID to advance B-cell approach to HIV vaccines 3Health News:Best Practice Database Adds Research on Merger Integration and Competitive Intelligence 2
... a persons attitude that determines how much exerc...perts at The Menninger Clinic. The researchers s...y enjoy it, and like the health benefits it provid...those participating in physical activities due to ...
...evated rate of increase in prostate specific antig...of aggressive form of prostate cancer, according t...he study suggests if the rate of PSA increase prio...y) is more than 2 ng/ml/year, it is an indication ...
...-day long festival for gays began in the capital o...over 20 films on homosexuality directed by many in...by panel discussions and a photographic presentati...gramme is to give voice to the issue in a country ...
... Buddhism and the Bible, Paris Hilton has adopted .... The jail bound socialite, who has to report to... June 5, was spotted wearing a T-shirt featuring a...Mary. In the past few days Paris has been spotted...
Other Medicine News:Health News:Attitude Determines How Much Exercise is too Much 2Health News:Scientists Identify the Most Significant Single Predictor of Aggressive Prostate Cancer 2Health News:Gay Film Festival Begins in Delhi 2
...e designed specifically for medical environments. ...logy with professional monitors, the LMD-151MD off... with key safety requirements and are ideal for us...logy and more. Slim and light, they can be used in...
...facial fixation. Completely resorbable, it present..., it is the most thoroughly proven product of its ...rb SE, with system enhancements that make it even ...system means that application of this proven techn...
PoleStar N-10 is a compact MRI unit that does not require a specially constructed surgery suite. The magnetic field is confined to the volume between the magnet poles and it's immediate neighborhood.
...) is a two-component surgical adhesive composed of...ehyde. The BSA is obtained from cattle exclusively...countries and undergoes processing that reduces or...by a controlled delivery system, composed of a reu...
Medicine Products: